Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

This study is testing whether adding targeted chemotherapy (GEMOX — gemcitabine + oxaliplatin) after surgery for gallbladder cancer, guided by genetic profiling of the tumor, improves survival in patients whose tumors show specific molecular changes. **You may be eligible if...** - You are Chinese and have been diagnosed with gallbladder carcinoma that was surgically removed - Your tumor has specific genetic mutations in the ERBB2 signaling pathway (identified by tumor sequencing) - You are in good physical condition (ECOG 0–1) - You have enough fresh tumor tissue available for genetic testing **You may NOT be eligible if...** - Your cancer is not resectable (surgically removable) - You do not have the required gene mutations - You have severe organ dysfunction or poor overall health - You are pregnant Talk to your doctor to see if this trial is right for you.